Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004052 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00004052: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00004052 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004052, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may make the body build an immune response to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.
Interventions
- BIOLOGICAL QS21
- BIOLOGICAL bcr-abl peptide vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 1999-03 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004052
The ClinicalTrials.gov registry entry for NCT00004052 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which QS21 is the first listed.
NCT00004052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004052 about?
NCT00004052 is a clinical study titled "Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia". RATIONALE: Vaccines may make the body build an immune response to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have chronic myelogenous leukemia.
What is the current status of trial NCT00004052?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 1999-03. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00004052?
The interventions under investigation include: QS21 (BIOLOGICAL), bcr-abl peptide vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004052?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.